Research at the MGH is interwoven throughout more than 30 departments, centers and units and is conducted with the support and guidance of the MGH Research Institute. The Research Roundup is a monthly series highlighting studies, news and events.
Departments, Centers, & Programs:
55 Fruit Street
Boston, MA 02114-2696
- MD, Baylor College of Medicine
- MS, Harvard School of Public Health
- Residency, Brigham and Women's Hospital
American Board Certifications
- Emergency Medicine, American Board of Emergency Medicine
Accepted Insurance Plans
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Dr. Filbin's interest focuses on early identification, characterization, and management of infection and sepsis. Dr. Filbin was site investigator and co-author on a practice-changing interventional trial in sepsis that aimed to validate protocolized goal-directed therapy with and without invasive monitoring versus standard of care (Protocolized Care for Early Septic Shock – Process ). This trial focused global attention on early sepsis detection as the potential key to making a difference in sepsis outcomes. Dr. Filbin was instrumental in conducting two related NIH-funded studies that both sought to characterize circulating serum protein profiles associated with short- and long-term outcomes (Endothelial Cell Signaling and Microcirculation in Sepsis and Protocolized Goal-directed Resuscitation of Septic Shock to Prevent Acute Kidney Injury - ProGReSS-AKI). Dr. Filbin recently co-authored a large multicenter trial investigating the role of procalcitonin in reducing antibiotic utilization in respiratory infections, and led MGH as the top enroller (Procalcitonin Antibiotic Consensus Trial – ProACT). Dr. Filbin currently coordinates enrollment at MGH in the Emergency Department for the PETAL Network trials (Prevention and Early Treatment of Acute Lung Injury).
- Sep | 7 | 2018
Sepsis is a disease that kills more than 258,000 Americans each year – that is more than prostate cancer, breast cancer and AIDS combined. Yet, for a disease that is so common and deadly, less than half of Americans have ever heard of sepsis.